Features of severe asthma response to anti-IL5/IL5r therapies : identikit of clinical remission
Copyright © 2024 Carpagnano, Portacci, Nolasco, Detoraki, Vatrella, Calabrese, Pelaia, Montagnolo, Scioscia, Valenti, D’Amato, Caiaffa, Triggiani, Scichilone and Crimi..
Introduction: Clinical remission (CliR) achievement has been recognized as a new potential outcome in severe asthma. Nevertheless, we still lack a detailed profile of what features could better identify patients undergoing clinical remission. In this study, we aim to address this issue, tracing a possible identikit of patients fulfilling remission criteria.
Methods: We enrolled 266 patients with severe eosinophilic asthma (SEA) treated with a 12-month course of anti-IL5/IL5 receptor (IL5r) monoclonal antibodies. Patients with no exacerbation, OCS withdrawal, ACT ≥ 20 and FEV1 ≥ 80% after 1 year of biologic treatment were classified as in clinical remission.
Results: 30.5% of the enrolled patients achieved remission after biologic administration. CliR group showed a lower number of baseline asthma exacerbations and better lung function parameters, with a trend for higher ACT scores and a less frequent history of a positive skin prick test. CliR achievement was unlikely in presence of a higher BMI, a positive skin prick test, an increased number of asthma exacerbations before biologic treatment, anti-muscarinic administration, and a previous diagnosis of EGPA, bronchiectasis or osteoporosis. In contrast, a better lung function, an increased blood eosinophilic count, the presence of chronic rhinosinusitis with nasal polyps and a more frequent use of reliever therapy predicts remission development. Changes in exacerbations number, OCS use, ACT scores and FEV1% between remittent and non-remittent patients arise at specific follow up timepoints and are positively associated with CliR achievement.
Discussion: anti-IL5/IL5r biologics can induce CliR in a proportion of patients with SEA. Patients achieving remission demonstrate specific clinical, functional and inflammatory features, as well as a specific moment of improvement in all the CliR items.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Frontiers in immunology - 15(2024) vom: 28., Seite 1343362 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Carpagnano, Giovanna Elisiana [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-IL5 |
|---|
| Anmerkungen: |
Date Completed 09.02.2024 Date Revised 10.04.2024 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fimmu.2024.1343362 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368167577 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368167577 | ||
| 003 | DE-627 | ||
| 005 | 20240411232318.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240208s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2024.1343362 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1372.xml |
| 035 | |a (DE-627)NLM368167577 | ||
| 035 | |a (NLM)38327518 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Carpagnano, Giovanna Elisiana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Features of severe asthma response to anti-IL5/IL5r therapies |b identikit of clinical remission |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.02.2024 | ||
| 500 | |a Date Revised 10.04.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Carpagnano, Portacci, Nolasco, Detoraki, Vatrella, Calabrese, Pelaia, Montagnolo, Scioscia, Valenti, D’Amato, Caiaffa, Triggiani, Scichilone and Crimi. | ||
| 520 | |a Introduction: Clinical remission (CliR) achievement has been recognized as a new potential outcome in severe asthma. Nevertheless, we still lack a detailed profile of what features could better identify patients undergoing clinical remission. In this study, we aim to address this issue, tracing a possible identikit of patients fulfilling remission criteria | ||
| 520 | |a Methods: We enrolled 266 patients with severe eosinophilic asthma (SEA) treated with a 12-month course of anti-IL5/IL5 receptor (IL5r) monoclonal antibodies. Patients with no exacerbation, OCS withdrawal, ACT ≥ 20 and FEV1 ≥ 80% after 1 year of biologic treatment were classified as in clinical remission | ||
| 520 | |a Results: 30.5% of the enrolled patients achieved remission after biologic administration. CliR group showed a lower number of baseline asthma exacerbations and better lung function parameters, with a trend for higher ACT scores and a less frequent history of a positive skin prick test. CliR achievement was unlikely in presence of a higher BMI, a positive skin prick test, an increased number of asthma exacerbations before biologic treatment, anti-muscarinic administration, and a previous diagnosis of EGPA, bronchiectasis or osteoporosis. In contrast, a better lung function, an increased blood eosinophilic count, the presence of chronic rhinosinusitis with nasal polyps and a more frequent use of reliever therapy predicts remission development. Changes in exacerbations number, OCS use, ACT scores and FEV1% between remittent and non-remittent patients arise at specific follow up timepoints and are positively associated with CliR achievement | ||
| 520 | |a Discussion: anti-IL5/IL5r biologics can induce CliR in a proportion of patients with SEA. Patients achieving remission demonstrate specific clinical, functional and inflammatory features, as well as a specific moment of improvement in all the CliR items | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a FEV1 | |
| 650 | 4 | |a anti-IL5 | |
| 650 | 4 | |a anti-IL5 receptor | |
| 650 | 4 | |a biologics | |
| 650 | 4 | |a clinical remission | |
| 650 | 4 | |a corticosteroids | |
| 650 | 4 | |a exacerbations | |
| 650 | 4 | |a severe asthma | |
| 650 | 7 | |a Receptors, Interleukin-5 |2 NLM | |
| 700 | 1 | |a Portacci, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Nolasco, Santi |e verfasserin |4 aut | |
| 700 | 1 | |a Detoraki, Aikaterini |e verfasserin |4 aut | |
| 700 | 1 | |a Vatrella, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Calabrese, Cecilia |e verfasserin |4 aut | |
| 700 | 1 | |a Pelaia, Corrado |e verfasserin |4 aut | |
| 700 | 1 | |a Montagnolo, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Scioscia, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Valenti, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a D'Amato, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Caiaffa, Maria Filomena |e verfasserin |4 aut | |
| 700 | 1 | |a Triggiani, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Scichilone, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Crimi, Claudia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d 2010 |g 15(2024) vom: 28., Seite 1343362 |w (DE-627)NLM215811453 |x 1664-3224 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g day:28 |g pages:1343362 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fimmu.2024.1343362 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |b 28 |h 1343362 | ||